RT Journal Article
SR Electronic
T1 Determinants of Antibody Levels and Protection against Omicron BQ.1/XBB Breakthrough Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.11.24315296
DO 10.1101/2024.10.11.24315296
A1 Pérez, Carla Martín
A1 Ramírez-Morros, Anna
A1 Jimenez, Alfons
A1 Vidal, Marta
A1 Pradenas, Edwards
A1 Barrios, Diana
A1 Canyelles, Mar
A1 Rubio, Rocío
A1 Cuamba, Inocencia
A1 Izquierdo, Luis
A1 Santamaria, Pere
A1 Trinité, Benjamin
A1 Vidal-Alaball, Josep
A1 Molinos-Albert, Luis M.
A1 Blanco, Julià
A1 Aguilar, Ruth
A1 Ruiz-Comellas, Anna
A1 Moncunill, Gemma
A1 Dobaño, Carlota
YR 2024
UL http://medrxiv.org/content/early/2024/10/11/2024.10.11.24315296.abstract
AB The ongoing evolution of SARS-CoV-2, particularly through the emergence of new variants, continues to challenge our understanding of immune protection. While antibody levels correlate with protection against earlier variants like Alpha and Delta, their relationship with Omicron sub-variants remains unclear. To investigate the role of antibody levels and neutralizing activity in preventing breakthrough infections, we analyzed longitudinal SARS-CoV-2 humoral responses and neutralizing activity against the ancestral virus and major emerging variants in a well-characterized cohort of healthcare workers in Spain (N = 405). We found that antibody levels and neutralization titers are key indicators of protection against SARS-CoV-2, including the BQ.1 and XBB Omicron variants. Higher IgG and IgA levels were associated with protection over three 6-month follow-up periods sequentially dominated by BA.1, BA.2, BA.5, BQ.1, and XBB Omicron sub-variants, although the strength of the association between antibody levels and protection declined over time. Our findings demonstrate that binding antibody levels and neutralizing responses are a valid correlate of protection against more evasive BQ.1 and XBB Omicron variants, although the strength of this association declined over time. Additionally, our results underscore the importance of continuous monitoring and updating vaccination strategies to maintain effective protection against emerging SARS-CoV-2 variants.Competing Interest StatementP. Santamaria is founder, scientific officer and stock holder of Parvus Therapeutics and receives funding from the company. He also has a consulting agreement with Sanofi. The other authors declare no competing interests.Funding StatementThis work was supported by the European Union under grant agreement no. 101046314 (END-VOC) and by the Fundacio Privada Daniel Bravo Andreu. C.M. was supported by the 100046TC21_2022 INV-1 00046 grant funded 535 by AGAUR/European Union NextGenerationEU/PRTR. R.R. had the support of the Health Department, Catalan Government (PERIS SLT017/20/000224). G.M. was supported by RYC 2020-029886-I/AEI/10.13039/501100011033, co-funded by European Social Fund (ESF). We acknowledge support from the grant CEX2023-0001290-S funded by MCIN/AEI/ 10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. The funders had no role in study design, data collection and analysis, the decision to publish, or the preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols were approved by the IRB Comite Etic de Investigacio Clinica IDIAP Jordi Gol (code 20/162-PCV), and written informed consent was obtained from all study participants before enrollment.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes